This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Chinook Therapeutics Dirección

Dirección controles de criterios 2/4

Chinook Therapeutics' CEO is Eric Dobmeier, appointed in Apr 2019, he has a tenure of 4.33 years. His total yearly compensation is $4.84M , comprised of 12.4% salary and 87.6% bonuses, including company stock and options. He directly owns 0.42% of the company’s shares, worth €11.11M. The average tenure of the management team and the board of directors is 2.2 years and 3.5 years respectively.

Información clave

Eric Dobmeier

Chief Executive Officer (CEO)

US$4.8m

Compensación total

Porcentaje del salario del CEO	12.4%
Permanencia del CEO	4.3yrs
Participación del CEO	0.4%
Permanencia media de la dirección	2.2yrs
Promedio de permanencia en la Junta Directiva	3.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Eric Dobmeier en comparación con los beneficios de Chinook Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2023	n/a	n/a	-US$246m
Mar 31 2023	n/a	n/a	-US$216m
Dec 31 2022	US$5m	US$601k	-US$188m
Sep 30 2022	n/a	n/a	-US$118m
Jun 30 2022	n/a	n/a	-US$92m
Mar 31 2022	n/a	n/a	-US$97m
Dec 31 2021	US$4m	US$547k	-US$103m
Sep 30 2021	n/a	n/a	-US$160m
Jun 30 2021	n/a	n/a	-US$149m
Mar 31 2021	n/a	n/a	-US$114m
Dec 31 2020	US$6m	US$438k	-US$82m

Compensación vs. Mercado: Eric's total compensation ($USD4.84M) is above average for companies of similar size in the German market ($USD2.55M).

Compensación vs. Ingresos: Eric's compensation has increased whilst the company is unprofitable.

CEO

Eric Dobmeier (54 yo)

4.3yrs

Permanencia

US$4,841,699

Compensación

Mr. Eric L. Dobmeier, J.D., has been an Independent Director at Structure Therapeutics Inc. since December 2022. He is the President, Chief Executive Officer and Director of Chinook Therapeutics, Inc. sinc...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Eric Dobmeier	President	4.3yrs	US$4.84m	0.42% $ 11.1m
Tom Frohlich	Chief Operating Officer	2.2yrs	US$2.02m	0.21% $ 5.6m
Andrew King	Chief Scientific Officer	2.2yrs	US$2.23m	0.027% $ 706.8k
Eric Bjerkholt	Chief Financial Officer	2.8yrs	sin datos	0.054% $ 1.4m
Sukhi Thethy	Senior Vice President of Finance & Accounting	less than a year	sin datos	sin datos
Noopur Liffick	Senior Vice President of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Kirk Schumacher	Senior VP & General Counsel	no data	sin datos	sin datos
Jodi Jamieson	Senior Vice President of Human Resources	no data	sin datos	sin datos
Alan Glicklich	Executive Officer	3.3yrs	US$2.41m	0.011% $ 291.2k
Delphine Imbert	Senior Vice President of CMC & Technical Operations	2.3yrs	sin datos	sin datos
Charlotte Jones-Burton	Senior Vice President of Product Development & Strategy	1.6yrs	sin datos	sin datos
Andrew Oxtoby	Chief Commercial Officer	less than a year	sin datos	sin datos

2.2yrs

Permanencia media

49yo

Promedio de edad

Equipo directivo experimentado: 290A's management team is considered experienced (2.2 years average tenure).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Eric Dobmeier	President	4.3yrs	US$4.84m	0.42% $ 11.1m
Michelle Griffin	Independent Director	2.8yrs	US$233.60k	0.0046% $ 121.9k
Srinivas Akkaraju	Independent Director	4.1yrs	US$227.60k	0.0046% $ 121.9k
William Greenman	Independent Director	13.2yrs	US$233.10k	0.033% $ 872.4k
Mahesh Krishnan	Independent Director	1.4yrs	US$451.98k	0.0018% $ 47.2k
Jerel Davis	Independent Lead Director	4.7yrs	US$244.60k	0.62% $ 16.5m
Robert Azelby	Independent Director	less than a year	sin datos	0% $ 0
Dolca Thomas	Independent Director	2.8yrs	US$217.60k	0.019% $ 490.7k

3.5yrs

Permanencia media

54.5yo

Promedio de edad

Junta con experiencia: 290A's board of directors are considered experienced (3.5 years average tenure).

This company listing is no longer active

Chinook Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Independent Lead Director recently sold €5.6m worth of stock

Chinook Therapeutics, Inc. Appoints Andrew Oxtoby as Chief Commercial Officer

President recently sold €175k worth of stock

Independent Director recently bought €212k worth of stock

High number of new directors

President recently bought €61k worth of stock

Recent updates

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

First quarter 2023 earnings released: US$0.85 loss per share (vs US$0.54 loss in 1Q 2022)

Independent Lead Director recently sold €5.6m worth of stock

Full year 2022 earnings released: US$2.87 loss per share (vs US$2.26 loss in FY 2021)

Chinook Therapeutics, Inc. Appoints Andrew Oxtoby as Chief Commercial Officer

President recently sold €175k worth of stock

Third quarter 2022 earnings released: US$0.83 loss per share (vs US$0.69 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.83 loss per share (vs US$0.69 loss in 3Q 2021)

Chinook Therapeutics, Inc. Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022

Independent Director recently bought €212k worth of stock

Second quarter 2022 earnings released: US$0.61 loss per share (vs US$0.97 loss in 2Q 2021)

High number of new directors

President recently bought €61k worth of stock

Chinook Therapeutics, Inc. Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at 59th European Renal Association Congress 2022

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022

First quarter 2022 earnings released: US$0.54 loss per share (vs US$0.88 loss in 1Q 2021)

High number of new directors

Chinook Therapeutics, Inc., Annual General Meeting, May 26, 2022

Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias

High number of new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Chinook Therapeutics, Inc. Announces Resignation of Alan Glicklich as Chief Medical Officer, Effective February 11, 2022

High number of new directors

President recently bought €101k worth of stock

Sairopa B.V., entered into an agreement to acquire non-renal assets of Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from Russell Microcap Growth Index

Chinook Therapeutics Presents BION-1301 Interim Phase 1/2 Data in Patients with IgA Nephropathy (IgAN) at the 58th ERA-EDTA Virtual Congress

Chinook Therapeutics, Inc. announced delayed annual 10-K filing

Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 Align Study of Atrasentan for Patients with Iga Nephropathy

Chinook Therapeutics, Inc. and Evotec SE Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases

Chinook Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Chk-336 for Treatment of Primary Hyperoxaluria

Chinook Therapeutics Announces License Agreement with Morehouse School of Medicine for Development of Therapies in Kidney Diseases Disproportionately Affecting African Americans and Underserved Communities

President recently bought €53k worth of stock

Chinook Therapeutics Announces Appointment of Eric Bjerkholt as Chief Financial Officer

Chinook Therapeutics, Inc. Provides Business Update

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad